Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 19;7(3):109.
doi: 10.3390/healthcare7030109.

A New Therapeutic Strategy for Recurrent Ovarian Cancer-Bevacizumab beyond Progressive Disease

Tadahiro Shoji  1 , Hisashi Eto  2 , Takanori Sato  3 , Rikako Soma  4 , Daisuke Fukagawa  5 , Hidetoshi Tomabechi  6 , Eriko Takatori  7 , Takayuki Nagasawa  8 , Seiya Sato  9 , Masahiro Kagabu  10 , Tsukasa Baba  11
Affiliations
Review

A New Therapeutic Strategy for Recurrent Ovarian Cancer-Bevacizumab beyond Progressive Disease

Tadahiro Shoji et al. Healthcare (Basel). .

Abstract

Treatment beyond progressive disease (PD) is a concept that even after drugs become ineffective, their continued use is more beneficial for patients than their discontinuation. In recent years, a concept of bevacizumab beyond PD (BBP) has attracted attention in the treatment of various cancers, and the usefulness of this concept has been evaluated. BBP has been proven to prolong overall survival (OS) in recurrent colorectal cancer and progression-free survival (PFS) in recurrent breast and lung cancers. With regard to the treatment of ovarian cancer, the MITO16/MaNGO-OV2B study (the Multicenter Phase III Randomized Study with Second Line Chemotherapy Plus or Minus Bevacizumab in Patients with Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line) was conducted in patients with platinum-sensitive recurrence and the JGOG3023 study (the Open-Label, Randomized, Phase II Trial Evaluating the Efficacy and Safety of Standard of Care with or Without Bevacizumab in Platinum-Resistant Ovarian Cancer Patients Previously Treated with Bevacizumab for Front-Line or Platinum-Sensitive Ovarian Cancer) was conducted in patients with platinum-resistant recurrence. The MITO16/MaNGO-OV2B study, reported in the 2018 annual meeting of the American Society of Clinical Oncology, showed that BBP achieved prolonged PFS. In the JGOG3023 study, enrollment of patients was completed in December 2018, and the follow-up period has been initiated. Proving the effectiveness of BBP in the treatment of ovarian cancer may provide a new therapeutic strategy and contribute to improved treatment outcomes in patients with poor prognosis and limited therapeutic options.

Keywords: JGOG3023; MITO16/MaNGO-OV2B; bevacizumab beyond PD; chemotherapy; recurrent ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
JGOG3023 Schema. Platinum-resistant ovarian cancer patients will be randomized 1:1 to treatment with chemotherapy alone or chemotherapy plus bevacizumab. *Defined as progression within < 6 months from completion of a minimum of three platinum therapy (including bevacizumab) cycles.
See this image and copyright information in PMC

References

    1. Folkman J. In: Cancer: Principles & Practice of Oncology. 7th ed. DeVita V.T. Jr., Hellman S., Rosenberg S.A., editors. Lippincott Williams & Wilkins; Philadelphia, PA, USA: 2005. pp. 2865–2882.
    1. Hanrahan V., Currie M.J., Gunningham S.P., Morrin H.R., Scott P.A., Robinson B.A., Fox S.B. The Angiogenic Switch for Vascular Endothelial Growth Factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the Adenoma-Carcinoma Sequence during Colorectal Cancer Progression. J. Pathol. 2003;200:183–194. doi: 10.1002/path.1339. - DOI - PubMed
    1. Fontanini G., Vignati S., Boldrini L., Chinè S., Silvestri V., Lucchi M., Mussi A., Angeletti C.A., Bevilacqua G. Vascular Endothelial Growth Factor is Associated with Neovascularization and Influences Progression of Non-Small Cell Lung Carcinoma. Clin. Cancer Res. 1997;3:861–865. - PubMed
    1. Tewari K.S., Sill M.W., Penson R.T., Huang H., Ramondetta L.M., Landrum L.M., Oaknin A., Reid T.J., Leitao M.M., Michael H.E., et al. Bevacizumab for Advanced Cervical Cancer: Final Overall Survival and Adverse Event Analysis of a Randomised, Controlled, Open-Label, Phase 3 Trial (Gynecologic Oncology Group 240) Lancet. 2017;390:1654–1663. doi: 10.1016/S0140-6736(17)31607-0. - DOI - PMC - PubMed
    1. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., et al. Bevacizumab Plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N. Engl. J. Med. 2004;350:2335–2342. doi: 10.1056/NEJMoa032691. - DOI - PubMed

LinkOut - more resources